Unnamed stage
$15m
Vaxxas gets $15m injection to develop needle-free vaccine
Biotech startup Vaxxas has raised $15 million in venture capital, led by OneVentures with Brandon Capital, MRCF and HealthCare Ventures, to commercialise the Nanopatch needle-free vaccine delivery technology developed at Queensland university institute AIBN.